OR WAIT null SECS
June 09, 2024
Artificial intelligence and machine learning can help overcome poor solubility and bioavailability.
June 08, 2024
The final drug product relies on the quality and reliability of the raw materials used in its production.
June 06, 2024
Biosimilar analytical assessments focus on demonstrating biosimilarity and interchangeability with the reference biologic.
June 04, 2024
Pharm Tech Group looks at the challenges surrounding the development and manufacture of ATMPs in more detail with Agne Vaitkeviciene, CEO of Memel Biotech.
Pharm Tech Group sits down with Bernard Sagaert, CEO of etherna, to examine the role of mRNA in the treatment of autoimmune diseases.
Pharm Tech Group chats with Dr. Monika Paulė, CEO and co-founder of Caszyme about the evolution of CRISPR.
May 30, 2024
A combination of rapid sterility methods with the industry standard compendial method should ensure maximum safety.
Bkemv (eculizumab-aeeb) is the first interchangeable biosimilar to Soliris (eculizumab) to treat paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
May 25, 2024
In an ASGCT Panel on nucleic acid- and cell-based vaccines in oncology, work on a personalized mRNA vaccine was highlighted.
The partnership aims to provide end-to-end development and manufacturing for biopharmaceutical drug substance and drug product.
